Daiichi Pharmaceutical Co Ltd having its head quarters located at Nihombashi, Chuo-ku in Tokyo, Japan was established on 10th of July, 1947. The main business of company is development of in-vitro diagnostics to support diagnoses. The company promotes pioneering strength build up resourceful techniques making all possible efforts for providing the hi-tech products that add to the realization of extended and healthy lives. Their business involves manufacturing and marketing medical diagnostic reagents for the lifestyle linked ailments and infectious diseases as key focused, based on the development capacities in the lipid sectors. The other key business of the company is to supporting R&D sectors of pharmaceutical companies at different stages of the pharmaceutical advancement sequences.

 

Daiichi is also one of the largest companies of Japan producing different types of prescription medicines. The product line covers various ailments such as infections, cancer, cardiovascular and intestinal disorders. The company has launched its products in the Chinese markets through its sales outlet in China. Daiichi Pharmaceutical of Beijing was established since 1995 and completed its pharmaceutical plant on 6^th June, 2000, situated within the economic and technological development area of Beijing.

 

This plant gives the company an integrated Chinese base for developing, producing and selling of the medicines. The main products being formulated in Daiichi plant are the antibacterial agent’s Cravit tablets, Translon tablets, Tarivid tablets and Cravit Injections. The company also enjoys the recognition of Good Manufacturing Practices-GMP. All the plants of Daiichi Group companies are working to hone their focal point on technological fields wherein they are typically expert and shift operations incorporating other technologies to the group plants that are ideally equipped for handling them for enhancing production efficacy.